Last checked at 14 Oct 2020 16:07
Iconic Labs Plc ("Iconic Labs" or the "Company")
Update on financing negotiations
Iconic Labs Plc (LSE:ICON), a multidivisional new media and technology business, today announces that, as part of the process of negotiations with European High Growth Opportunities Fund ("EHGOF") in respect of the debts owed to EHGOF, the Company has today formally terminated all contracts and other arrangements between the Company and EHGOF, with immediate effect. This is consistent with and follows from the Company's previously announced intention not to issue any further drawdown notices under the EHGOF facility. Notwithstanding the termination, the accrued debt to EHGOF remains, and negotiations in respect of the settlement of this debt continue. The Company will provide further updates in due course.
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by the Company to constitute inside information for the purposes of the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
**ENDS**
For further information, please visit the Company's website www.iconiclabs.co.uk or contact:
Damon Heath | Shard Capital Partners LLP | Tel: +44 (0) 20 7186 9950 |
Iconic Labs ir@iconiclabs.co.uk
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END